{"abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products.\" FDA is issuing this draft guidance as part of a series of guidance documents under its Real-World Evidence (RWE) Program and to satisfy, in part, a mandate under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to issue guidance about the use of RWE in regulatory decision-making. This draft guidance includes recommendations to sponsors and investigators considering the use of externally controlled trials to provide evidence of the safety and effectiveness of a drug product. The draft guidance also describes considerations related to communicating with FDA and ensuring access by the Agency to data from an externally controlled trial.","action":"Notice of availability.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2023/02/01/2023-02094.html","cfr_references":[],"citation":"88 FR 6748","comment_url":null,"comments_close_on":"2023-05-02","correction_of":null,"corrections":[],"dates":"Submit either electronic or written comments on the draft guidance by May 2, 2023 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.","disposition_notes":null,"docket_ids":["Docket No. FDA-2022-D-2983"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":0,"comment_start_date":"2023-02-01","updated_at":"2023-02-25T00:29:56.760-05:00","comment_url":"https://www.regulations.gov/commenton/FDA-2022-D-2983-0001","allow_late_comments":null,"id":"FDA-2022-D-2983-0001","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2022-D-2983","title":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products; Draft Guidance for Industry; Availability"}],"document_number":"2023-02094","effective_on":null,"end_page":6750,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2023/02/01/2023-02094.xml","html_url":"https://www.federalregister.gov/documents/2023/02/01/2023-02094/considerations-for-the-design-and-conduct-of-externally-controlled-trials-for-drug-and-biological","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2023-02094?publication_date=2023-02-01","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2023-02-01/2023-02094/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":2036,"last_updated":"2026-04-04 14:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-02-01/pdf/2023-02094.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-02094.pdf?1675172730","publication_date":"2023-02-01","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2023/02/01/2023-02094.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2022-D-2983","supporting_documents_count":0,"docket_id":"FDA-2022-D-2983","document_id":"FDA-2022-D-2983-0001","regulation_id_number":null,"title":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products; Draft Guidance for Industry; Availability","checked_regulationsdotgov_at":"2023-03-01T19:12:10Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":6748,"subtype":null,"title":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products; Draft Guidance for Industry; Availability","toc_doc":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products","toc_subject":"Guidance:\n","topics":[],"type":"Notice","volume":88}